Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Predicting Tamoxifen Resistance In Patients
Tamoxifen is a widely used and highly successful drug in the treatment of breast cancer, though resistance to tamoxifen is still a concern in recurrent disease (affecting 25-35% of patients), since therapy resistant metastatic tumor cells are a major cause of death. In a study in this month"s Molecular and Cellular Proteomics, researchers have uncovered a protein profile that may accurately predict whether a cancer will be tamoxifen resistant.
generic viagra online
Perceptive Informatics Enhances Investigator Application Of New RECIST Version In Imaging-Based Oncology Trials
Perceptive Informatics, the industry"s leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), announced the launch of a website designed to help investigators apply the new 1.1 version of RECIST (Response Evaluation Criteria In Solid Tumors) in medical imaging-based oncology trials.
News of the day
GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results At Endocrine Society Annual Meeting
GTx, Inc. (Nasdaq: GTXI) announced results of a Phase II clinical trial evaluating Ostarine™ (MK-2866), an investigational selective androgen receptor modulator (SARM), in patients with cancer induced muscle loss, also known as cancer cachexia. In the study, Ostarine treatment led to statistically significant increase in lean body mass (LBM) and improvement in muscle performance measured by stair climb in patients with cancer cachexia compared to baseline in both the Ostarine 1 mg and 3 mg treatment cohorts. These study results were the subject today of an oral podium presentation at the 2009 Annual Meeting of the Endocrine Society in Washington.
Medical Devices

President Obama Joins In Chorus Of Complaints About CBO Figures

President Barack Obama joins the chorus of Democrats who criticize Congressional Budget Office numbers and claim that their analyses estimates aren"t fair. The criticism comes after the agency provided $1 to $1.6 trillion estimates for two of the Democrats" draft health care reform bills. ABC News reports on the question of whether President Obama will dismiss whatever price tag the CBO eventually attaches to the final version of the congressional Democrats" proposal: "The reason politicians and their staffers are wondering is because for the first time, last night the president expressed frustration at the way CBO - long regarded as a fair and non-partisan arbiter - makes its analyses." Some Democrats, such as Sen. Chris Dodd, D-Conn., expressed frustration that the CBO doesn"t factor in cost-savings from prevention programs or their other health benefits. Meanwhile, President Obama also talked about the CBO estimates and "promised that "about two-thirds of the cost would be covered by reallocating dollars that are already in the health care system -- taxpayers are already paying for it -- but it"s not going to stuff that"s making you healthier." Roughly a third more "will come from new revenue" - a tax increase on wealthier individuals." He also noted that the hard figures don"t "count all the savings that may come from prevention, may come from eliminating all the paperwork and bureaucracy because we"ve put forward health IT, it doesn"t come from the evidence-based care and changes in reimbursement that I"ve already discussed about. ... The CBO, which sort of polices what all various programs cost, they"re not willing to credit us with those savings" (Tapper, 6/25). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009